James Mackin Sells 13,936 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) CEO James Mackin sold 13,936 shares of the firm’s stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $35.69, for a total value of $497,375.84. Following the completion of the sale, the chief executive officer directly owned 766,095 shares in the company, valued at $27,341,930.55. This trade represents a 1.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Artivion Stock Up 6.6%

Shares of AORT stock opened at $38.14 on Friday. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $48.25. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. The firm has a market cap of $1.83 billion, a PE ratio of 190.71 and a beta of 1.59. The stock has a 50 day moving average of $42.09 and a 200-day moving average of $43.05.

Artivion (NYSE:AORT) last announced its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. The business had revenue of $118.30 million for the quarter, compared to analyst estimates of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The company’s revenue for the quarter was up 19.2% compared to the same quarter last year. On average, equities analysts predict that Artivion, Inc. will post 0.37 EPS for the current year.

More Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q4 results topped expectations — revenue grew ~19% year‑over‑year and EPS beat consensus, supporting revenue momentum and margin recovery; this helps justify the current rally. Earnings & Company Page
• Positive Sentiment: Short interest fell ~15.4% in February to ~1.39M shares (~3.2% of float); lower short exposure reduces one source of downside selling and can make up‑moves easier to sustain. Short Interest/Insider Page
• Positive Sentiment: Institutional investors have increased or initiated positions in recent quarters (multiple funds cited), indicating professional conviction that could support longer‑term demand. Institutional Holdings
• Neutral Sentiment: Analyst coverage is mixed — consensus is a “Moderate Buy” with an average target near $49, but some shops have trimmed targets or moved to Hold, reflecting divergent views on near‑term upside. Analyst Notes
• Negative Sentiment: Large, broad insider selling across Feb. 23–24 (CEO James P. Mackin, EVP Lance Berry, SVPs and CAO made sizable open‑market disposals). While filings suggest open‑market liquidity/scheduled sales rather than insider panic, the scale and breadth can create short‑term selling pressure and investor unease. SEC filings: CEO Form 4 and related officer filings. CEO Form 4 EVP Form 4

Analysts Set New Price Targets

AORT has been the topic of a number of recent research reports. Needham & Company LLC reissued a “buy” rating and set a $58.00 target price on shares of Artivion in a research report on Monday, February 2nd. Oppenheimer reissued an “outperform” rating and set a $50.00 price objective on shares of Artivion in a report on Friday, November 7th. Canaccord Genuity Group cut their target price on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Wall Street Zen cut Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Citizens Jmp boosted their price target on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $48.97.

Institutional Trading of Artivion

Large investors have recently bought and sold shares of the stock. Aster Capital Management DIFC Ltd raised its stake in Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after acquiring an additional 519 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Artivion during the 3rd quarter worth about $27,000. Larson Financial Group LLC increased its position in shares of Artivion by 148.5% during the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after purchasing an additional 563 shares in the last quarter. USA Financial Formulas lifted its holdings in Artivion by 163.5% during the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after purchasing an additional 703 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its position in Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after buying an additional 538 shares in the last quarter. 86.37% of the stock is currently owned by institutional investors.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.